Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 1;50(9):1406-1408.
doi: 10.1097/CCM.0000000000005604. Epub 2022 Aug 15.

Moving to the Head of the "Claza"-Targeting Interleukin-6 for COVID-19 Pneumonia

Ciara M Shaver  1
Affiliations
Editorial

Moving to the Head of the "Claza"-Targeting Interleukin-6 for COVID-19 Pneumonia

Ciara M Shaver. Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. National Center for Health Statistics: In-hospital Mortality Among Hospital Confirmed COVID-19 Encounters by Week from Selected Hospitals. Available at: https://www.cdc.gov/nchs/covid19/nhcs/hospital-mortality-by-week.htm. Accessed May 12, 2022.
    1. Lonze BE, Spiegler P, Wesson RN, et al. : A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation. Crit Care Med 2022; 50:1348–1359 - PMC - PubMed
    1. Weinblatt ME, Mease P, Mysler E, et al. : The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: Results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 2015; 67:2591–2600 - PubMed
    1. Doberer K, Duerr M, Halloran PF, et al. : A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol 2021; 32:708–722 - PMC - PubMed
    1. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021;397:1637–1645 - PMC - PubMed